The rapid acceleration of New Approach Methodologies (NAMs) in drug safety testing has, for many, appeared to be a sudden shift, propelled by recent regulatory mandates and an increasing internal drive within pharmaceutical organizations. This perception, often fueled by landmark legislative changes such as the FDA Modernization Act 2.0 in 2022, suggests an overnight embrace of non-animal methods. However, this transformative moment is not an abrupt pivot but rather the culmination of over a decade of intensive scientific research, technological innovation, and dedicated regulatory groundwork, particularly evident in the critical domain of cardiac safety assessment.
The Genesis of a Paradigm Shift: Addressing Traditional Limitations
The impetus for NAMs originated from a long-standing recognition of the inherent limitations of traditional safety models, predominantly animal-based assays. Despite decades of refinement and significant investment, these models frequently struggled to accurately predict human physiological responses, leading to persistently high rates of late-stage drug attrition due to safety liabilities. Cardiac risk, in particular, represented a formidable challenge, with unforeseen cardiotoxicity being a significant cause of drug withdrawals and clinical trial failures, incurring substantial financial losses and delaying the availability of potentially life-saving therapies. Historically, drugs like terfenadine (Seldane), cisapride (Propulsid), and mibefradil (Posicor) were withdrawn from the market due to their propensity to cause serious, sometimes fatal, cardiac arrhythmias, underscoring the urgent need for more predictive preclinical safety assessments.
Early in the 21st century, the scientific community began coalescing around the idea that human-relevant, mechanism-based in vitro assays could offer a superior predictive capability. Initiatives launched in the early-to-mid 2010s, such as the U.S. Environmental Protection Agency’s (EPA) ToxCast program and the collaborative Tox21 project, pioneered the high-throughput screening of thousands of chemicals against hundreds of molecular targets and pathways using in vitro human cell lines. These programs established a critical principle: by moving closer to human biology and focusing on specific mechanisms of toxicity, these "new approach methodologies" could potentially equal or even exceed the predictive power of traditional animal models when applied appropriately.
The FDA Modernization Act 2.0: A Regulatory Watershed, Not a Starting Point
When the FDA Modernization Act 2.0 was signed into law in December 2022, it was widely interpreted as a landmark moment for NAMs. The legislation explicitly removed the statutory requirement for animal testing in drug development, instead allowing sponsors to use "non-animal tests" or "other technologies" when appropriate. While this act indeed marked a pivotal shift in regulatory policy, it was not a sudden embrace of untested methodologies. Rather, it was a formal acknowledgment by the U.S. regulatory body that the scientific, technical, and regulatory groundwork for NAMs had been meticulously laid over many years. The Act provided the necessary legal framework to encourage and validate the adoption of these advanced tools, signaling a clear path forward for pharmaceutical innovators.
Before the Act, pharmaceutical companies often found themselves in a challenging position. While many recognized the scientific merit of NAMs and used them internally to guide discovery and early development, they hesitated to rely on them for formal regulatory submissions due to the lack of clear guidance and precedent. This began to change with the development of formal regulatory engagement mechanisms. The FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program, for instance, created a structured framework for dialogue between regulators, industry stakeholders, and technology developers. ISTAND allowed for the pre-submission evaluation of novel methodologies, fostering alignment on what constitutes "fit-for-purpose" evidence and building confidence in NAMs for regulatory use. This program became instrumental in bridging the gap between scientific innovation and regulatory acceptance, demonstrating the FDA’s proactive role in facilitating this transition long before the Modernization Act.
Cardiac Safety: A Vanguard for NAM Maturity
Among the various domains of drug safety, cardiac safety has emerged as one of the clearest and most compelling demonstrations of what regulatory-ready NAMs can achieve. The reason lies in the profound value of functional, human-derived physiology in safety decision-making for the heart. The complexity of cardiac electrophysiology and the devastating consequences of drug-induced arrhythmias necessitate highly accurate and predictive models.
At the forefront of this advancement are human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (hiPSC-CMs) coupled with Microelectrode Array (MEA) technology. This pairing allows for the continuous, noninvasive monitoring of cardiac electrophysiology in vitro, providing functional data that are both physiologically relevant and operationally practical for pharmaceutical and contract research organizations (CROs). Platforms like the Maestro MEA system have played a central role in this evolution, offering scalable workflows for high-throughput screening.
A critical initiative that cemented the credibility of these assays was the Comprehensive in vitro Proarrhythmia Assay (CiPA) program. Launched in 2013 as a collaborative effort involving regulators (FDA, EMA, PMDA), industry (PhRMA, HESI), and academia, CiPA aimed to improve the prediction of drug-induced torsades de pointes (TdP) risk, a rare but potentially fatal ventricular arrhythmia. CiPA recognized that the traditional hERG assay, while valuable, was insufficient on its own. The program proposed a new paradigm combining hERG, multi-ion channel pharmacology, in silico modeling, and hiPSC-CM assays.
Two pivotal multicenter CiPA studies, involving numerous pharmaceutical companies, CROs, and academic institutions worldwide, rigorously evaluated the performance of hiPSC-cardiomyocyte MEA assays. These studies conclusively demonstrated that the assays could reliably detect delayed repolarization and arrhythmia-like events associated with TdP risk. The robust findings directly informed the ICH E14/S7B Questions & Answers document, finalized in 2022, which formally recognized hiPSC-CM data as valuable supportive evidence for proarrhythmic risk assessment. This was a monumental achievement, translating cutting-edge science into globally accepted regulatory guidance. CiPA not only validated the mechanistic and functional superiority of these assays but also underscored the imperative of translating this science into reproducible, scalable workflows usable across diverse organizations.
Accelerated Adoption and Demonstrable Value
The growing confidence in functional NAMs is now manifesting in accelerated adoption across the industry. A recent regulatory milestone further underscores this progress: a letter of intent submitted by Axion BioSystems for a human iPSC-derived cardiomyocyte MEA assay was accepted into the FDA’s ISTAND program. This acceptance is not merely a procedural step; it reflects years of sustained investment across industry and academia in functional electrophysiology and regulatory science. It signifies a broader effort to translate human-relevant physiology into tools that can reliably support regulated safety workflows, offering a clear path for other developers.
Quantifiable data supports this trend. A 2025 study authored by FDA scientists found a significant increase in the number of Investigational New Drug (IND) applications submitted with iPSC-CM data over the past decade. Notably, between 2020 and 2023, the number of submissions including hiPSC-CM MEA assays doubled compared with the total number submitted prior to 2020. This dramatic acceleration reflects a clear industry shift towards integrating these advanced approaches into drug development programs.
Further reinforcing the predictive power of these methods, a new paper, currently under review, highlights that hiPSC-CM data demonstrated strong concordance with clinical QT outcomes. Crucially, it showed higher predictive performance than commonly required methods, including hERG assays, multi-ion channel approaches, and traditional animal QT studies. The study went further, demonstrating that using hiPSC-CM data in combination with other in vitro assays reduced nonclinical QT false negatives and provided predictive value comparable to multiple animal studies. This groundbreaking finding opens the potential for hiPSC-CM MEA assays to replace additional animal studies, offering both ethical and efficiency benefits.
Perhaps the most striking indicator of value is the voluntary uptake of these technologies. hiPSC-cardiomyocyte MEA data are not currently mandated for IND submissions. Yet, sponsors are increasingly choosing to include these studies, driven by their ability to provide superior insights. This voluntary adoption speaks volumes about the real value these assays deliver, helping drug development teams reduce uncertainty, mitigate risk, and make better-informed safety decisions earlier in the pipeline. This trend is further evidenced by the fact that at least 16 contract research organizations (CROs) now offer CiPA-style hiPSC-CM assays as a standard service, often utilizing the Maestro Pro MEA system, indicating a robust and professionalized ecosystem supporting these advanced methodologies.
Ensuring Consistency and Future Scalability: The AIMS Initiative
As functional NAMs transition from validation into broader regulatory use, the next critical challenge is ensuring consistency. Variability in model performance and interpretation across different laboratories or experimental setups could quickly erode the hard-won confidence in these methods if expectations are not clearly defined. To address this, initiatives like the Axion iPSC Model Standards (AIMS) have emerged. AIMS is a collaborative effort involving leaders in the safety field, focused on defining meaningful functional standards for hiPSC-CM assays. The goal is to establish clear benchmarks for baseline electrophysiological performance, acceptable variability, and expected responses to reference compounds. Such standardization is essential for NAMs to scale responsibly, provide reliable data across the industry, and seamlessly integrate into future regulatory frameworks. These efforts, from the foundational CiPA program to IND inclusion, from ISTAND engagement to the AIMS initiative, collectively illustrate how cardiac safety has become a model for NAM maturity and successful adoption. They demonstrate a path forward built on rigorous science, collaborative regulatory engagement, and a shared commitment to standards grounded in human-relevant physiology.
Implications for Drug Development and Patient Safety
The managed transition towards functional NAMs presents both significant opportunities and responsibilities for safety leaders within pharmaceutical organizations. The opportunity lies in adopting tools that provide earlier, more human-relevant insights into cardiac risk, thereby reducing the likelihood of costly late-stage failures. This translates into more efficient drug development timelines and potentially lower overall R&D costs. By identifying potential cardiotoxicity earlier, companies can either mitigate the risk through structural modifications or terminate problematic compounds before significant investment has been made, saving hundreds of millions of dollars per failed drug.
Furthermore, the implications for patient safety are profound. More accurate preclinical prediction of cardiac adverse events means that safer drugs can reach patients faster, minimizing the risk of severe side effects post-market launch. This shift fundamentally redefines the toxicology paradigm, moving away from merely descriptive animal studies towards a more mechanistic, human-centric understanding of drug effects. It aligns drug development with societal expectations for both ethical treatment of animals and the delivery of safer medicines.
Mike Clements, PhD, SVP Scientific Partnerships & Strategy at Axion BioSystems, whose early research with Maestro MEA systems and stem cell-derived cardiomyocytes helped inform the CiPA initiative, emphasizes the evolutionary nature of this shift. "The real risk today is relying on approaches that haven’t kept pace with what we now know about human cardiac biology," Clements states. He highlights that the tools now entering safety workflows are not unproven novelties but have been meticulously shaped by years of validation, cross-sector collaboration, and substantial investment in regulatory science. Platforms that combine proven performance, robust regulatory engagement, and a commitment to standardization offer a path forward that is evolutionary rather than disruptive, integrating seamlessly into existing drug development processes while enhancing their predictive power.
In conclusion, the journey of functional NAMs in cardiac safety exemplifies a scientific and regulatory success story built on strong foundations. These methodologies are not just alternatives to traditional animal testing; they represent a superior, more predictive approach grounded in human-relevant biology. By providing earlier, more accurate insights into cardiac risk, functional NAMs are accelerating drug development, reducing costs, and ultimately delivering safer, more effective medicines to patients. This managed transition, supported by continuous scientific advancement, regulatory foresight, and industry collaboration, marks a new era in drug safety assessment.
Leave a Reply